AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00598091
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, Days 1, 8, 15
Trial: NCT00598091
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg, PO, QD
Trial: NCT00598091
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, days 1, 8, 15
Trial: NCT00598091
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg, PO, BID
Trial: NCT02108301
Drug: tacrolimus-cyclosporine A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
Trial: NCT02465450
Drug: JBT-101 (lenabasum)
RxNorm normalized name: JBT-101
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
Trial: NCT02830139
Drug: Normal saline , Cisplatin , 5-Fu
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03273062
Drug: Tolcapone 200 MG
RxNorm normalized name: tolcapone 200 MG
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone 200 MG TID
Trial: NCT05002361
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24 mg intravenous Dexamethasone (6 ml)
Trial: NCT04511130
Drug: MT-401
RxNorm normalized name: MT-401
DrugBank: MT-401 (DB18639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
Trial: NCT00674947
Drug: BIIB015
RxNorm normalized name: BIIB015
DrugBank: BIIB015 (DB06304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion once every 3 weeks until disease progression or unacceptable toxicity
Trial: NCT00417066
Drug: Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00236821
Drug: levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00060411
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00060411
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00915174
Drug: Neramexane
RxNorm normalized name: Neramexane
DrugBank: Neramexane (DB04926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
Trial: NCT00830128
Drug: pregabalin (Lyrica)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
Trial: NCT00111761
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
Trial: NCT00111761
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.
Trial: NCT02728323
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
Trial: NCT02728323
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of saline saline by intramuscular injection, at the end of surgery
Trial: NCT02051868
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
Trial: NCT02051868
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
Trial: NCT02051868
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
Trial: NCT02051868
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
Trial: NCT00232934
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01515319
Drug: Y242
RxNorm normalized name: Yttrium (90Y) ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)
Trial: NCT01423903
Drug: OPB-51602
RxNorm normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
Trial: NCT05253014
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous paracetamol every 8 hours
Trial: NCT01181973
Drug: pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
Trial: NCT01181973
Drug: pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
Trial: NCT02471846
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
Trial: NCT02471846
Drug: GDC-0919
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
Trial: NCT00058903
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03806049
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: given orally once daily
Trial: NCT03806049
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: given as iv infusion every three weeks
Trial: NCT03806049
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given as iv infusion every three weeks
Trial: NCT03806049
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: given as iv infusion every three weeks
Trial: NCT01672983
Drug: ABT-450/ritonavir, ABT-267
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ABT-450 (tablet) dosed with ritonavir (capsule), and ABT-267 (tablet)
Trial: NCT02386852
Drug: Ginseng
RxNorm normalized name: Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
Trial: NCT00240045
Drug: Midodrine, albumin, octreotide LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00240045
Drug: midodrine, octreotide, albumin
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
Trial: NCT02386852
Drug: Ginkgo Biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
Trial: NCT02868385
Drug: 4x Praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
Trial: NCT02868385
Drug: 1x Praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One praziquantel treatment (40 mg/kg) at baseline
Trial: NCT01528501
Drug: Panobinostat (LBH589)
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00160043
Drug: SH T00268C
RxNorm normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg experimental drug od
Trial: NCT02373865
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin will be given in a daily dosage of 100 mg
Trial: NCT02373865
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
Trial: NCT02373865
Drug: Sitagliptin-Placebo
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
Trial: NCT02373865
Drug: Glimepiride-Placebo
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
Trial: NCT03244592
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT03674606
Drug: Low dose aspirin
RxNorm normalized name: Adult Low Dose Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 75 mg aspirin dose taken daily
Trial: NCT04447846
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.
Trial: NCT00640081
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03131583
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day-14\~Day16 qd
Trial: NCT03131583
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Day1 and Day8 qd
Trial: NCT00074971
Drug: Fabrazyme (agalsidase beta)
RxNorm normalized name: agalsidase beta Injection [Fabrazyme]
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04298021
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500 mg iv on D1 Every 4 weeks
Trial: NCT04298021
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg bid on D1-28 Every 4 weeks
Trial: NCT00495586
Drug: Amoxicillin and clavulanic acid
RxNorm normalized name: Amoxicillin and clavulanic acid only product
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500-125 mg to be taken every eight hours for 8 days
Trial: NCT02429050
Drug: sustained release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
Trial: NCT02313051
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: mTOR inhibitor
Trial: NCT02313051
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02313051
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004547
Drug: Postoperative dwell with paclitaxel and 5-FU
RxNorm normalized name: 5-FU
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal dwell chemotherapy with a combination of 5-FU and Paclitaxel will be delivered in the early postoperative period (day 7 today 12 after surgery). Patients will be premedicated with hydrocortisone (100 mg/intravenous push (i.v.p.)), diphenhydramine (50 mg i.v.p.) and ranitidine (50 mg i.v.p.) 30 minutes prior to delivering intraperitoneal chemotherapy. One liter of normal saline will be infused containing 5-FU (800 mg/M\^2) and 1 L of normal saline containing paclitaxel (125 mg/M\^2) will be infused over 60 minutes. The chemotherapy solution will be left in the abdominal cavity permanently for slow absorption.
Trial: NCT00819520
Drug: ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
Trial: NCT01655316
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01443169
Drug: Sequence 1 - Treatment A: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 1 - Treatment B: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 1 - Treatment C:Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 1 - Treatment D: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 1 - Treatment E: Immediate Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg IR capsule administered in the evening in the fasted state.
Trial: NCT01443169
Drug: Sequence 2 - Treatment B: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 2 - Treatment D: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 2 - Treatment A: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 2 - Treatment C: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 2 - Treatment E: Immediate Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg IR capsule administered in the evening in the fasted state.
Trial: NCT01443169
Drug: Sequence 3 - Treatment C: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 3 - Treatment A: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 3 - Treatment D: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT01443169
Drug: Sequence 3 - Treatment B: Controlled Release Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Trial: NCT00819520
Drug: malathion
RxNorm normalized name: Malathion
DrugBank: Malathion (DB00772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
Trial: NCT02527343
Drug: volanesorsen
RxNorm normalized name: Volanesorsen
DrugBank: Volanesorsen (DB15067)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
Trial: NCT01029652
Drug: Canakinumab 150 mg
RxNorm normalized name: canakinumab 150 MG/ML
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
Trial: NCT01029652
Drug: Triamcinolone acetonide 40 mg
RxNorm normalized name: triamcinolone acetonide 40 MG/ML
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 40 mg was supplied as a suspension.
Trial: NCT01029652
Drug: Placebo to canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
Trial: NCT01029652
Drug: Placebo to triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
Trial: NCT00509678
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Trial: NCT00211185
Drug: Denileukin diftitox
RxNorm normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.